IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease

Gothenburg, Sweden, February 26, date, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, today announces that the first patient has been dosed in a Phase Ib study with IRL757 – a potential new treatment for Parkinson’s disease-related apathy. This event triggers a USD 3 million milestone payment to IRLAB, payable in instalments in 2026. The study is fully funded by IRLAB’s development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) – an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd.

IRLAB publishes full-year report for the period January – December 2025

IRLAB has received scientific advisory board confirmation on next steps for pirepemat